Clear Cell Sarcoma
Symptoms, Doctors, Treatments, Advances & More

Clear Cell Sarcoma Overview

Save information for later
Sign Up

Learn About Clear Cell Sarcoma

What is the definition of Clear Cell Sarcoma?
Clear cell sarcoma is a rare subtype of a cancer called soft tissue sarcoma. It is called clear cell sarcoma because the cancer cells have a clear appearance when viewed under a microscope.
What are the symptoms of Clear Cell Sarcoma?
Initially, clear cell sarcoma may not have any symptoms. Symptoms of clear cell sarcoma include the appearance of a lump under the skin that can be painful, usually on the thigh, leg, or ankle. Additional symptoms of clear cell sarcoma include unexplained weight loss, fatigue, and night sweats.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Clear Cell Sarcoma?
Treatments for clear cell sarcoma include surgery, radiation therapy, and chemotherapy.
Who are the top Clear Cell Sarcoma Local Doctors?
Elite in Clear Cell Sarcoma
Elite in Clear Cell Sarcoma
Referral may be required
Milan, IT 

Silvia Stacchiotti practices practicing medicine in Milan, Italy. Ms. Stacchiotti is rated as an Elite expert by MediFind in the treatment of Clear Cell Sarcoma. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Hemangioendothelioma, Epithelioid Sarcoma, and Synovectomy.

Elite in Clear Cell Sarcoma
Elite in Clear Cell Sarcoma
Referral may be required
Cracow Branch, 
Krakow, MA, PL 

Piotr Rutkowski practices practicing medicine in Krakow, Poland. Mr. Rutkowski is rated as an Elite expert by MediFind in the treatment of Clear Cell Sarcoma. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Melanoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Lymphadenectomy, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Clear Cell Sarcoma
Distinguished in Clear Cell Sarcoma
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Chad Lagrange is a Urologist practicing medicine in Omaha, Nebraska. Dr. Lagrange is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Reconstructive Urology Surgery, and Nephrectomy. Dr. Lagrange is currently accepting new patients.

View All Doctors
What are the latest Clear Cell Sarcoma Clinical Trials?
Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors
Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 02, 2026

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screen...

Match to trials
Find the right clinical trials for you in under a minute
Get started
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Enrollment Status: Recruiting
Publish Date: August 03, 2026
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1/Phase 2

Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, with or without RT. * To characterize the pharmacokinetics of pazopanib and doxorubicin in combination with ifosfamide in inte...

View All Clinical Trials